An investigation on behalf of investors in NeoGenomics, Inc. (NASDAQ:NEO) shares over potential wrongdoing at NeoGenomics, Inc. was announced and NASDAQ:NEO stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 03/12/2018 -- An investigation was announced for investors in shares of NeoGenomics, Inc. (NASDAQ:NEO) was announced over potential breaches of fiduciary duties by certain directors at NeoGenomics, Inc.
Investors who purchased shares of NeoGenomics, Inc. (NASDAQ:NEO) have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain NeoGenomics, Inc. (NASDAQ:NEO officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
Fort Myers, FL based NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. NeoGenomics, Inc. reported that its annual Total Revenue rose from $244.08 million in 2016 to $258.61 million in 2017 and that its Net Loss declined from $5.72 million in 2016 to $0.85 million in 2017.
Shares of NeoGenomics, Inc. (NASDAQ:NEO) increased from $3.88 per share in January 2015 to as high as $11.13 per share in September 2017.
On March 9, 2017, NASDAQ:NEO shares closed at $8.71 per share.
Those who purchased shares of NeoGenomics, Inc. (NASDAQ:NEO), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels